Autor: Firma Cardior Pharmaceuticals

Independent Peer-Reviewed Study Validates Therapeutic Mode of Action of Cardior’s First-in-Class Heart Failure Program

Firma Cardior PharmaceuticalsPosted in AllgemeinTagged , , , , , , , , , , , , , ,

Cardior Pharmaceuticals GmbH, a clinical-stage biotech company focused on the development of non-coding RNA (ncRNA) based therapeutics for patients with cardiovascular diseases, announced today that a recent peer-reviewed study confirms […]

Weiterlesen

Cardior Pharmaceuticals‘ Lead Compound Demonstrates Improvement of Heart Function in Chronic Heart Failure Model

Firma Cardior PharmaceuticalsPosted in MedizintechnikTagged , , , , , , , , , , , , , ,

Safety and efficacy of CDR132L established in an in vivo model of chronic post-MI heart failure Study by international research team published in European Heart Journal Broad treatment potential for […]

Weiterlesen

Cardior Pharmaceuticals Demonstrates Reversal of Cardiac Hypertrophy by H19 Gene Therapy

Firma Cardior PharmaceuticalsPosted in MedizintechnikTagged , , , , , , , , , , , , , ,

Administration of AAV9 expressing H19 attenuates cardiac hypertrophy in vivo and prevents progression to heart failure Details on novel mechanism of action published in peer-reviewed study in the European Heart […]

Weiterlesen